Summit Therapeutics Inc. (SMMT) Research

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.

Market snapshot

Symbol
SMMT
Price
$13.75
Day change
-2.27%
Market cap
$10.7B
P/E ratio
-10.13x
52-week range
12.55-30.98
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$19.50

Recent news

  • The Era of the One-Size-Fits-All Cancer Drug Is Ending

    Investors have bet new drugs can topple Merck's Keytruda, but the evidence so far points to something smaller.

  • What's Going On With Summit Therapeutics Stock On Monday?

    Summit Therapeutics Inc. (NASDAQ:SMMT) stock is down on Monday following the recent announcement regarding the clinical trial results of ivonescimab on Sunday.

  • Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

    Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients ​live 15% longer than BeOne Medicines' Tevimbra immunotherapy.

Peer companies

  • Ascendis Pharma A/S (ASND)
  • BridgeBio Pharma, Inc. (BBIO)
  • Exact Sciences Corporation (EXAS)
  • Ionis Pharmaceuticals, Inc. (IONS)
  • Moderna, Inc. (MRNA)
  • Atrium Therapeutics, Inc. (RNA)
  • Roivant Sciences Ltd. (ROIV)
  • Royalty Pharma plc (RPRX)

Recent insider activity

  • Zanganeh Mahkam — P-Purchase (3810000 shares) on 2026-06-12
  • DUGGAN ROBERT W — P-Purchase (3810000 shares) on 2026-06-12
  • DUGGAN ROBERT W — P-Purchase (100000 shares) on 2026-06-04
  • Zanganeh Mahkam — P-Purchase (100000 shares) on 2026-06-04
  • Soni Manmeet Singh — P-Purchase (25000 shares) on 2026-06-04

Open Summit Therapeutics Inc. (SMMT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.